KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Sales (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Sales for 12 consecutive years, with 46.94% as the latest value for Q4 2025.

  • Quarterly Return on Sales changed N/A to 46.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.94% through Dec 2025, changed N/A year-over-year, with the annual reading at 46.94% for FY2025, N/A changed from the prior year.
  • Return on Sales for Q4 2025 was 46.94% at Xenon Pharmaceuticals, down from 41.51% in the prior quarter.
  • The five-year high for Return on Sales was 0.43% in Q4 2022, with the low at 321.53% in Q2 2023.
  • Average Return on Sales over 4 years is 61.55%, with a median of 23.87% recorded in 2025.
  • Peak annual rise in Return on Sales hit 641bps in 2022, while the deepest fall reached -27801bps in 2022.
  • Over 4 years, Return on Sales stood at 6.84% in 2021, then soared by 94bps to 0.43% in 2022, then plummeted by -74210bps to 321.53% in 2023, then surged by 85bps to 46.94% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 46.94%, 41.51%, and 37.76% for Q4 2025, Q3 2025, and Q2 2025 respectively.